Published in Exp Cell Res on December 15, 2005
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol (2007) 1.55
The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol (2011) 1.46
Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer (2012) 1.41
Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther (2009) 1.36
Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol (2006) 1.18
Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer (2008) 1.09
Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer (2008) 1.09
Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev (2011) 1.09
Regulation of prolactin receptor levels and activity in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.07
Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer (2007) 1.07
Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget (2014) 1.05
Cyanidin-3-glucoside inhibits ethanol-induced invasion of breast cancer cells overexpressing ErbB2. Mol Cancer (2010) 1.04
Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. Endocrinology (2011) 0.96
Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br J Pharmacol (2007) 0.96
Ethanol enhances the interaction of breast cancer cells over-expressing ErbB2 with fibronectin. Alcohol Clin Exp Res (2010) 0.89
The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer (2012) 0.89
Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat (2010) 0.87
Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag Res (2013) 0.86
Anticancer mechanisms of cannabinoids. Curr Oncol (2016) 0.86
Changes in the endocannabinoid system may give insight into new and effective treatments for cancer. Vitam Horm (2009) 0.83
Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cells. Br J Pharmacol (2013) 0.78
The endocannabinoid system and sex steroid hormone-dependent cancers. Int J Endocrinol (2013) 0.77
Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis. J Biol Chem (2015) 0.77
Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol (2008) 0.76
Protopine inhibits heterotypic cell adhesion in MDA-MB-231 cells through down-regulation of multi-adhesive factors. Afr J Tradit Complement Altern Med (2014) 0.76
Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. Front Pharmacol (2016) 0.75
Anti‑carcinogenic activity of anandamide on human glioma in vitro and in vivo. Mol Med Rep (2015) 0.75
Roles of Eicosanoids in Prostate Cancer. Future Lipidol (2008) 0.75
Endocannabinoids as Guardians of Metastasis. Int J Mol Sci (2016) 0.75
Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions. Biomed Res Int (2015) 0.75
The influence of biomechanical properties and cannabinoids on tumor invasion. Cell Adh Migr (2016) 0.75
Anandamide inhibits breast tumor-induced angiogenesis. Transl Med UniSa (2014) 0.75
Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent. Breast Cancer (Dove Med Press) (2016) 0.75
Identification of biological targets of therapeutic intervention for clear cell renal cell carcinoma based on bioinformatics approach. Cancer Cell Int (2016) 0.75
Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer. Naunyn Schmiedebergs Arch Pharmacol (2017) 0.75
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol (2003) 3.60
The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov (2004) 3.47
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A (2002) 3.16
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab (2006) 2.72
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 2.54
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
Possible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 1.89
Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem (2004) 1.87
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Endocannabinoids and the control of energy balance. Trends Endocrinol Metab (2006) 1.74
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain (2011) 1.70
The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab (2013) 1.67
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med (Berl) (2007) 1.65
Biochemistry and pharmacology of endovanilloids. Pharmacol Ther (2007) 1.64
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther (2006) 1.61
An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology (2003) 1.60
Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther (2005) 1.56
Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol (2009) 1.55
Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology (2006) 1.54
Insulin stimulates fibroblast proliferation through calcium-calmodulin-dependent kinase II. Cell Cycle (2009) 1.53
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2011) 1.53
Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci (2004) 1.52
Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) (2008) 1.51
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J (2005) 1.48
N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem (2003) 1.48
Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A (2008) 1.47
Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev (2011) 1.44
Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology (2002) 1.41
Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci (2003) 1.41
Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells. Eur J Cancer (2013) 1.39
Radioiodide induces apoptosis in human thyroid tissue in culture. Endocrine (2013) 1.39
Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr (2009) 1.39
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res (2002) 1.38
Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci (2006) 1.37
Calmodulin-dependent kinase IV links Toll-like receptor 4 signaling with survival pathway of activated dendritic cells. Blood (2007) 1.37
Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab (2004) 1.36
An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab (2009) 1.36
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J (2006) 1.36
The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab (2011) 1.35
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs (2010) 1.34
Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology (2005) 1.33
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta (2006) 1.31
Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J Physiol (2006) 1.30
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol (2003) 1.30
Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol (2008) 1.30
A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab (2012) 1.30
Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis (2003) 1.29
Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol (2003) 1.29
An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Angew Chem Int Ed Engl (2011) 1.26
The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav (2005) 1.25
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther (2008) 1.25
Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One (2011) 1.24
The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol (2006) 1.24
Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol (2002) 1.24
Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol (2007) 1.24
Acute presentation of spinal epidural cavernous angiomas: case report. Neurosurgery (2007) 1.24
Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. Eur J Pharmacol (2004) 1.24
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf) (2013) 1.22
Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem (2002) 1.22
Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) (2007) 1.21
Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology (2008) 1.21
A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J (2004) 1.21
Evolutionary origins of the endocannabinoid system. Gene (2006) 1.21
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21
TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des (2008) 1.21
The endocannabinoid signaling system in cancer. Trends Pharmacol Sci (2013) 1.20
Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci (2007) 1.20
N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie (2010) 1.19
Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets (2010) 1.19
Calcium/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation. J Biol Chem (2003) 1.19
Endocannabinoids link feeding state and auditory perception-related gene expression. J Neurosci (2004) 1.18
Fine-needle cytology of Hürthle cell tumors and morphometry. Cancer Cytopathol (2014) 1.18
Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol (2006) 1.18
TRPV1 channels control synaptic plasticity in the developing superior colliculus. J Physiol (2009) 1.17
Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem (2008) 1.16